<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

News

Jump to a page: Press Releases Media Kit

Biodesix secures Oncimmune

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Biodesix Looks to Become ‘the’ Lung Cancer Detection Co. With New Acquisition

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Immodulon adopts AI tool to accelerate pancreatic cancer clinical trial

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Biodesix, Immodulon team up for pancreatic cancer treatment

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Multivariate Blood Test Can Predict Outcomes for Non-Small Cell Lung Cancer

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Medical Device and Diagnostic Industry

Data suggest that a blood-based test from Biodesix has the potential to detect pretreatment risk of anti-PD-1 immunotherapy resistance among NSCLC patients

Clinical Omics

Data suggest that a blood-based test from Biodesix has the potential to detect pretreatment risk of anti-PD-1 immunotherapy resistance among NSCLC patients

Fierce Biotech

Data suggest that a blood-based test from Biodesix has the potential to detect pretreatment risk of anti-PD-1 immunotherapy resistance among NSCLC patients

Clinical Lab Products: Test Predicts Primary Resistance to Anti-PD-1 Immunotherapy against Non-Small Cell Lung Cancer

Data suggest that a blood-based test from Biodesix has the potential to detect pretreatment risk of anti-PD-1 immunotherapy resistance among NSCLC patients

DDNews: VeriStrat proves its prognostic capabilities

Dr. Skibo discusses how ddPCR-based liquid biopsy could be the solution to treatment delays due to receiving genetic information late